Campylobacter jejuni vaccine - Emergent BioDefense Operations Lansing

Drug Profile

Campylobacter jejuni vaccine - Emergent BioDefense Operations Lansing

Alternative Names: CAMPYVAX

Latest Information Update: 02 Sep 2015

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Emergent BioDefense Operations Lansing
  • Developer Emergent BioDefense Operations Lansing; United States Army Medical Research Institute of Infectious Diseases
  • Class Bacterial vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Campylobacter infections

Most Recent Events

  • 16 Jun 2003 The assets of Antex Biologics and Antex Pharma have been acquired by BioPort Corporation
  • 05 Nov 2001 A phase II trial conducted in collaboration with the US Department of Defense has been completed
  • 19 Oct 2001 Antex Biologics has completed phase I trials funded by the US Army SBIR and the US Army has invited Antex to submit an application for phase II trials
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top